X-linked Hypophosphatemic Rickets/Osteomalacia
Conditions
Sponsors
Kyowa Kirin Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Personally submitted voluntary written informed consent by a legally authorized representative. If appropriate, written or verbal assent to participate in the study should be obtained from patients. 2) Aged >=1 and == 30 pg/mL 6) Finding evidence of rickets (e.g. a cup-shaped depression of the metaphyseal end, enlargement of the epiphyseal line, fuzzing) or clinical symptoms such as X-legs and O-legs, by the judgment of investigator, in the simple X-ray evaluation at screening 7) Meeting all of following criteria for laboratory test related to XLH; a) Serum P: = 16 ng/mL 8) For female patients who have reached menarche with child bearing potential; a negative urine pregnancy test at screening 9) For female patients with child baring potential, or male patients with reproductive capacity; willingness to use an acceptable method of contraception while participating in the study 10) Willingness to provide access to prior medical records to determine eligibility including data on imaging tests, blood chemistry, diagnosis, medication, and surgical history 11) Willingness and ability to cooperatively complete all study procedures, adhere to the visit schedule and follow the investigator instructions, as considered by the investigator or subinvestigator
Exclusion criteria
Exclusion criteria: 1) Height percentile > 50% based on age-adjusted Japanese norms at screening 2) Use of aluminum hydroxide antacids, systemic corticosteroids, acetazolamide, and thiazides within 7 days prior to screening 3) Current or prior use of leuprorelin, triptorelin, goserelin, or other drugs known to delay puberty 4) Use of growth hormone therapy within 12 months before screening 5) Use of medication to suppress parathyroid hormone (e.g., cinacalcet) within 60 days prior to screening 6) Serum calcium levels outside the age-adjusted normal limits 7) Evidence of hyperparathyroidism (iPTH levels >= 163 pg/mL) 8) Presence of nephrocalcinosis on renal ultrasound grade 4 based on the following scale: 0 = Normal 1 = Faint hyperechogenic rim around the medullary pyramids 2 = More intense echogenic rim with echoes faintly filling the entire pyramid 3 = Uniformly intense echoes throughout the pyramid 4 = Stone formation: solitary focus of echoes at the tip of the pyramid 9) Planned or recommended orthopedic surgery (implantation or removal), including staples, 8 plates or osteotomy, during the study period 10) Blood or blood product transfusion within 60 days prior to screening 11) History of malignancy within 5 years prior to registration 12) History of being positive for HIV antibody, HBs antigen and/or HCV antibody 13) Predisposition to infection, or history of recurrent infection or known immunodeficiency 14) Use of any investigational product or investigational medical device within 4 months prior to screening, or requirement for any investigational agent prior to completion of all scheduled study assessments 15) Recieving investigational agent in the UX023-CL301 study 16) Use of a therapeutic monoclonal antibody other than KRN23 within 90 days prior to screening 17) History of allergic or anaphylactic reactions to KRN23, any of the KRN23 ingredients, or any other monoclonal antibodies 18) Anyone otherwise considered unsuitable participation in the study by the investigator or subinvestigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety AEs, lab values, vital signs, ECG, renal ultrasound, ECHO | — |
Secondary
| Measure | Time frame |
|---|---|
| other - | — |
Countries
Japan
Outcome results
None listed